医学
免疫疗法
鼻咽癌
肿瘤微环境
头颈部癌
肿瘤科
癌症
临床试验
内科学
免疫系统
放射治疗
免疫学
头颈部鳞状细胞癌
作者
Sophie Outh-Gauer,Marie Alt,Christophe Le Tourneau,Jérémy Augustin,Chloé Broudin,Cassandre Gasne,Thomas Denize,H. Mirghani,Elizabeth Fabre,M. Ménard,Florian Scotté,Éric Tartour,Cécile Badoual
标识
DOI:10.1016/j.ctrv.2018.02.008
摘要
Cancer occurrence can be understood as the result of dysfunctions in immune tumoral microenvironment. Here we review the recent understandings of those microenvironment changes, regarding their causes and prognostic significance in head and neck (HN) carcinoma. We will focus on HN squamous cell cancer (SCC) and nasopharyngeal carcinomas (NPC). Their overall poor prognosis may be improved with immunotherapy in a subset of patients, as supported by current clinical trials. However, finding reliable markers of therapeutic response is crucial for patient selection, due to potential severe adverse reactions and high costs. Half of HNSCC exhibit PD-L1 expression, this expression being higher in HPV-positive tumors. In recent clinical trials, a better therapeutic response to anti-PD-1 was obtained in patients with higher PD-L1 expression. The Food and Drug Administration (FDA) approved the use of these therapeutics without stating a need for patient selection regarding PD-L1 status. Activation status, density and localization of TIL as well as PD-L2, γ-interferon, inflammatory cytokines, epithelial-mesenchymal transition phenotype and mutational burden may all be potential therapeutic response markers. In Epstein-Barr Virus (EBV)-induced nasopharyngeal non-keratinizing cancer, PD-L1 is over-expressed compared to EBV-negative tumors. A 22% response rate has been observed under anti-PD-1 treatment among PD-L1-positive NPC patients. A better understanding of immune checkpoint regulation processes may allow patients to benefit from these promising immunotherapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI